Expedeon
英國Expedeon www.expedeon.com
Expedeon Ltd, (formerly Novexin)was founded in 2003 by two biochemical engineers from University of Cambridge, Dr Daniel Jones and Dr Heikki Lanckriet. They recognised the severe problems which exist in producing high quality protein products and invented a radical new approach to circumvent the problems. Background technology was acquired from the University and then further developed within Expedeon.
Initial funding of £10,000 was won in the Cambridge Enterprise 2003 Business Creation Competition. Private investment of £1.35m was raised in two funding rounds. Further funding (£0.25m) was secured as awards from the UK Department of Trade and Industry for innovative research and development.
Expedeon is based on patented technology that has the power to radically improve and change the way that proteins are produced and refolded, particularly in the biopharmaceuticals area.
Expedeon's initial products are laboratory kits that enable researchers to produce recombinant proteins more rapidly and reliably. Using its novel carbohydrate molecules Expedeon is further developing its technology and products to improve other aspects of protein production and analysis.
In additional to selling laboratory products the company undertakes collaborative research and development projects and licenses partners to apply the technology in product development and in production.
